

Chapter	sub-chapter	Drug	Spend increase	Spend increase (%)	Volume change (%)	Narrative	indication of patient numbers (latest yr)
Central Nervous System	Analgesia	Nefopam	£ 41,000	320	0.08	Original brand Accupan was discontinued followed by shortages of the generic.	850
	Anti-epileptics	Pregabalin	£ 32,000	15	16	Lyrica High Court appeal due in June/July 2017. (Patent expiry expected July 2017).	1617
	Antidepressants	Trazodone	£ 50,400	151	5.7	Generic shortages (particularly of the liquid version). Only ever used as 3rd or 4th line - very rarely a suitable alternative.	863
Cardiovascular	Anticoagulants	Apixaban	£ 37,000	78	106	Formulary change to 1st line	358
		INR testing	£ 7,000	51	44	near patient testing	
		Rivaroxaban	£ 6,700	20	40	Formulary change to 2nd line	130
		Warfarin	£ 1,000	7	0.9		2086
	Lipid regulating drugs	Rosuvastatin	£ 6,000	18	18	Formulary change	346
		Atorvastatin	£ 2,800	11	17	Formulary change	6562
Endocrine	Diabetes	New oral meds	£ 46,000	59	4.4	Driven primarily by Pioglitazone generic shortage and the resultant reliance on 2nd/3rd line alternatives	412
		Metformin	£ 9,000	17	6.7		3645
		Diagnostic testing	-£ 19,000	-14.4	6.5	Switch to TrueYou test strips and continuing decrease in urine testing	
	Steroids	Hydrocortisone	£ 10,900	33	15	Shortages	102
		Fludrocortisone	£ 4,500	848	17		102
	Thyroid therapy	Levothyroxine	£ 4,000	6	5	Tariff pricing	5180
Anti-thyroids		£ 7	32	16	Tariff pricing	194	